Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep investors engaged” over the next 12-24 months and while Eylea-HD, or high dose, is “off to a good start,” standard Eylea headwinds could lead to declining franchise growth, the analyst tells investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron announces new, updated data from hematology pipeline at ASH
- Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer
- Regeneron, Sanofi announce EC approval for Dupixent
- Regeneron price target lowered to $1,126 from $1,137 at Truist
- Regeneron price target lowered to $1,215 from $1,260 at RBC Capital